Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate.
14C-labelled clofibric acid and fenofibric acid were administered p.o. to 200 g male and female rats. After 10 h, liver nuclear DNA and protein were isolated and the radioactivity was determined. Binding to protein was clearly measurable whereas no binding to DNA could be detected from any drug. A comparison of the limit of detection of such DNA binding with well-known chemical carcinogens revealed that the known hepatocarcinogenicity of clofibrate cannot be based upon an initiating, DNA damaging, mode of action but must be due to other, nongenotoxic, mechanisms such as peroxisome proliferation, hepatomegaly, or cytotoxicity due to protein binding. The risk assessment in man and the interpretation of the carcinogenicity data for rodents are discussed.
D000818:Animals; D002273:Carcinogens / Q000378:metabolism; D002994:Clofibrate / Q000378:metabolism* / Q000633:toxicity; D004247:DNA / Q000378:metabolism*; D005260:Female; D011345:Fenofibrate / Q000031:analogs & derivatives / Q000378:metabolism* / Q000633:toxicity; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D011422:Propionates / Q000378:metabolism*; D011485:Protein Binding; D051381:Rats
D002273:Carcinogens; D011422:Propionates; D004247:DNA; C006012:fenofibric acid; D002994:Clofibrate; D011345:Fenofibrate